TREATMENT SEQUENCING PATTERNS AND COSTS OF CARE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
Author(s)
Potluri R1, Farr AM2, Hirji I3, Davis C4, Bhandari H5, Oukessou A4
1SmartAnalyst Inc., New York, NY, USA, 2Truven Health Analytics, Bethesda, MD, USA, 3Bristol-Myers Squibb, Wallingford, CT, USA, 4Bristol-Myers Squibb, Princeton, NJ, USA, 5SmartAnalyst India (Pvt.) Ltd., Gurgaon, India
OBJECTIVES: To evaluate treatment sequences and associated costs among patients with relapsed/refractory multiple myeloma (RRMM). METHODS: Patients with RRMM between January 2007 and September 2013 were identified from US MarketScan databases. Outcomes included treatment regimen per line (L; 2–4L), sequences of treatment regimens, and cost per line and of progression (2L vs >2L). All-cause and MM-specific monthly costs captured inpatient, outpatient, emergency department, and drug-related costs, adjusted for censoring. RESULTS:
Conference/Value in Health Info
2015-11, ISPOR Europe 2015, Milan, Italy
Value in Health, Vol. 18, No. 7 (November 2015)
Code
PCN118
Topic
Economic Evaluation
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies
Disease
Oncology, Systemic Disorders/Conditions